# To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions

> **NCT00883155** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Bupropion HCl 100 mg Tablets (Invamed Inc.)
- **DRUG:** Wellbutrin 100 mg Tablets (Glaxo Wellcome)

## Key facts

- **NCT ID:** NCT00883155
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-10
- **Primary completion:** 1998-10
- **Final completion:** 1998-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00883155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00883155, "To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00883155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*